Courtney DiNardo, MD | Aplastic Anemia & MDS International Foundation

Courtney DiNardo, MD

Position / Title: 
Associate Professor, Department of Leukemia, Division of Cancer Medicine
Institution: 
MD Anderson Cancer Center
Primary Disease Area of Focus: 
  • acute myeloid leukemia (AML)
  • aplastic anemia
  • myelodysplastic syndromes (MDS)

Dr. DiNardo is a clinical researcher with a specialized focus on prognostication and personalized therapeutics for patients with myeloid malignancies. She has completed formal training in epidemiology and biostatistics, with a Master’s of Science in Clinical Epidemiology obtained in June 2012. Her thesis involved an analysis of isocitrate dehydrogenase (IDH) mutations, serum 2-hydroxyglutarate (2HG) levels, and patient outcomes in AML, performed in collaboration with the Eastern Cooperative Oncology Group (ECOG). Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted therapeutic agents currently in clinical trials. Dr DiNardo is also involved in the clinical development of the BCL2-inhibitor venetoclax (ABT-199) for myeloid malignancies. She is leading the study of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML patients. In addition, Dr. DiNardo’s clinical and research focus pertaining to hereditary cancer predisposition syndromes has led to the development of the MD Anderson Hereditary Hematologic Malignancy Clinic, which now provides clinical and research-based evaluation of underlying cancer predispositions and hereditary cancer syndromes in leukemia patients.

Practice Location: 
University of Texas MD Anderson Cancer Center
Houston , TX 77030
US
Physician Status: 
  • accepting new patients